Market Newsdesk

Dynamic positioning systems manufacturer Navis Engineering will offer KVH Watch services to enable remote monitoring of equipment

Disrupted by COVID-19, German Enterprises Speed Up Digital Transformation to Compete Under New Conditions

ISG Provider Lens™ report finds companies setting more aggressive digitalization timelines to reap benefits in manufacturing, supply chains, customer service and other areas

FRANKFURT, Germany–(BUSINESS WIRE)–
Changes wrought by the COVID-19 pandemic have accelerated enterprise digital transformation programs in Germany by months or years, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.

The 2021 ISG Provider Lens™ Digital Business – Solutions and Service Partners report for Germany finds German companies faced with pandemic-era changes to supply chains, work modes, manufacturing processes and customer service are responding with new technologies and organizational approaches. Digital business services and solutions that utilize AI, machine learning, automation and other new technologies are on the rise, often deployed across hybrid clouds and over software-defined networks that enable secure edge computing.

“Enterprises in Germany are revamping their operations and business practices to remain competitive post-pandemic,” said Anna Medkouri, partner, ISG EMEA, in Germany. “Providers are partnering with German companies to accomplish this quickly, especially in the country’s large manufacturing, engineering and supply-chain sectors.”

Digital services offer several advantages that have led German enterprises to choose them over less digitalized approaches, the report says. These include guaranteed service performance, predictive analysis, automated customer engagement and sustainability.

Many German engineering and manufacturing firms are undergoing digital transformations to achieve guaranteed service delivery at any utilization rate and on any platform, ISG says. Automated, predictive provisioning tools provide for reliable service delivery over software-defined networks and both wireline and wireless infrastructure, including narrowband IoT (NB-IoT) networks, which are quickly gaining popularity in Germany.

Self-monitoring, reporting and forecasting capabilities are increasingly important for detecting and solving problems, often with machine learning, the report says. Germany’s supply chain and manufacturing sectors are especially motivated to implement these systems and share the collected data with relevant team members through DevOps methods.

In the German retail and financial industries, digital transformation often means introducing virtual assistants and chatbots and utilizing highly automated and distributed customer experience services. These services can be provided by remote agents in secured environments, including employees’ homes, using new tools such as advanced environmental monitoring.

Digital services are also helping German companies achieve sustainability and decarbonization goals, which are becoming more critical as potential tax increases and regulatory issues loom on the horizon. These may include consulting and advisory services, monitoring and dashboards, and in some cases, larger initiatives such as clean energy supply systems or new office configurations to reduce carbon footprints.

The 2021 ISG Provider Lens™ Digital Business – Solutions and Service Partners report for Germany evaluates the capabilities of 44 providers across four quadrants: Digital Business Consulting Services, Digital Customer Experience Services, Digital Supply Chain Transformation Services and Sustainability and Decarbonization Services.

The report names Accenture, Arvato Systems, Atos, IBM and T-Systems as Leaders in all four quadrants. It names Capgemini and Infosys as Leaders in three quadrants each and Cognizant, DXC Technology and Siemens as Leaders in two quadrants each. Axians, CGI, Computacenter, HCL and Publicis Sapient are named as Leaders in one quadrant each.

In addition, Tech Mahindra and TietoEVRY are named as Rising Stars—companies with a “promising portfolio” and “high future potential” by ISG’s definition—in one quadrant each.

A customized version of the report is available from T-Systems.

The 2021 ISG Provider Lens™ Digital Business – Solutions and Service Partners report for Germany is available to subscribers or for one-time purchase on this webpage.

About ISG Provider Lens™ Research

The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

A companion research series, the ISG Provider Lens Archetype reports, offer a first-of-its-kind evaluation of providers from the perspective of specific buyer types.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005230/en/

Press:

Philipp Jaensch, ISG

+49 151 730 365 76

[email protected]

Matthias Longo, Palmer Hargreaves for ISG

+49 152 341 464 63

[email protected]

KEYWORDS: Germany Europe

INDUSTRY KEYWORDS: Technology Networks Other Technology Data Management

MEDIA:

Logo

Over Half of Crypto-Natives Would Rather Get Paid Their Salary in Cryptocurrency, Research Published by Paysafe Shows

Out of the 30 million+ crypto owners in the U.S. & U.K.*, 55% would like to get paid their full salary in crypto rather than fiat currencies

LONDON–(BUSINESS WIRE)–Paysafe (NYSE: PSFE), a leading specialized payments platform, has today released new research which reveals that 55% of crypto owners – rising to 60% of 18-24 year olds – would rather get paid their salary in cryptocurrency. The top reasons for this include people seeing cryptocurrencies as a smart investment, believing that they’ll likely get paid in it soon anyway, and greater financial flexibility. The research ‘Inside the crypto community: Plotting the journey to mass adoption’ surveyed a cross section of 2,000 crypto owners living in the U.S. and U.K., including their attitudes towards the future of decentralized finance.

Over half (54%) of crypto owners agree that cryptocurrency is the future of finance and will take over as the dominant form of international currency. This was also the primary motivation for owning crypto in the first place, ahead of making money from trading or investing. However, the research suggests this conclusion has come through careful consideration – and that crypto owners have had concerns along the way. In fact, 70% of people admitted to having doubts about investing in crypto at some point since they started trading, with nearly half (49%) of all crypto owners having cashed out either some or all of their cryptocurrency assets at some point as a result.

According to crypto owners, payments hold the key to mass crypto adoption. The top reason for not wanting to be paid in cryptocurrency is that it can’t be used to make payments widely enough at present (24%). Additionally, 22% of all crypto owners said they would invest more in crypto if more retailers accepted it as a form of payment, and 17% said the same if more countries accepted cryptocurrencies as legal tender. Overall, 59% of respondents agree that the lack of real-world applications for cryptocurrencies, such as payments, is currently preventing crypto from reaching its full potential.

Despite some of these potential stumbling blocks, crypto owners are optimistic on the timeline to widespread adoption. Over half (60%) agree that you’ll be able to use crypto to make online purchases with many more online retailers this time next year, while 47% agree that accepting cryptocurrencies in physical stores will become commonplace within the next 12 months. Finally, nearly half of crypto owners (49%) believe that everyone will own cryptocurrency within the next five years.

Commenting on the findings, Chirag Patel, CEO, Digital Wallets at Paysafe, said: “Interest in defi and the metaverse has reached a whole new level recently and, with that, positive sentiment towards cryptocurrencies continues to increase. However, it’s clear that many people are still crying out for more practical use cases to bring crypto into the real world – in particular, being able to use it as a payment method, and this is something we are committed to driving at Paysafe. People can interact with cryptocurrencies through our digital wallets, Skrill and NETELLER, whether that’s for the very first time or as a more seasoned investor.”

For further information download the full report here: www.paysafe.com/blog/inside-the-crypto-community

###

NOTES TO EDITORS

*As published in https://triple-a.io/crypto-ownership/

About the research

This research was commissioned by Paysafe, and conducted by independent research house Sapio Research in October 2021. The research was collected using an email invitation and online survey.

The research was conducted among 2,015 consumers living in either the UK or U.S. (minimum of 1,000 respondents in each country). Only respondents that confirmed that they currently owned one or more cryptocurrencies, or had done at any point previously, were able to participate in the survey. This sample was selected in order to more accurately reflect the actions and opinions of those with first-hand knowledge of cryptocurrencies. The demographics of respondents (age and gender) are a representative sample of the total crypto community (consumers that own or have owned cryptocurrencies), rather than a nationally representative sample.

The sample was selected from online partner panels. The results of any sample are subject to sampling variation.

About Paysafe Limited

Paysafe Limited (“Paysafe”) (NYSE: PSFE) (PSFE.WS) is a leading specialized payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, and online cash solutions. With over 20 years of online payment experience, an annualized transactional volume of U.S. $100 billion in 2020, and approximately 3,400 employees located in 12+ global locations, Paysafe connects businesses and consumers across 70 payment types in over 40 currencies around the world. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics and the convergence between brick-and-mortar and online payments.

Further information is available at www.paysafe.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005137/en/

Anna Howard, Director of Communications, Europe and Asia, Paysafe

[email protected]

Phone: +442038908975

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Finance Data Management Professional Services Technology Software

MEDIA:

Logo

Logitech Signature M650 Mouse Offers a More Personalized Experience and a Left-Handed Option

Select your size and work all day in comfort with SmartWheel scrolling

LAUSANNE, Switzerland & NEWARK, Calif.–(BUSINESS WIRE)–
Today Logitech (SIX: LOGN) (NASDAQ: LOGI) introduced the new Signature M650 Wireless Mouse and Signature M650 for Business Wireless Mouse, a comfortable and personalized mouse with two different sizes and a left-handed option, offering a better experience for more people. The wireless mouse is designed to upgrade any desk setup and improve the overall work experience with features like SmartWheel scrolling, nearly silent clicks and a contoured comfort design that enables faster, more comfortable work than ever before.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005225/en/

“There are more than a billion knowledge workers in the world, and around half of them don’t use a mouse or have an entry level or corded mouse with limited functions,” said Art O’Gnimh, vice president of the mainstream business for creativity and productivity at Logitech. “The Signature M650 offers a true Logitech signature experience with simple productivity functions that make working all day easier and faster.”

Whether working on a document or browsing through a website, the Signature M650’s SmartWheel helps to deliver precision when needed and speed in an instant. The Signature M650 and larger size Signature M650 L also feature SilentTouch technology, reducing click noise by 90% compared to the Logitech M185 Mouse, ideal when clicking during a video call. Enjoy a strong wireless connection and a battery that lasts up to two years, giving you complete peace of mind.

With two sizes and a left-handed option, a contoured shape, a soft thumb area and rubber side grip, the Signature M650 inclusive design allows you to work comfortably for extended hours and gives you the ability to customize the side buttons to favorite shortcuts with Logitech Options+. The Signature M650, available in off-white, graphite and rose, works with Windows, macOS, Linux, Chrome OS, ipadOS and Android operating systems. Connect in an instant via Bluetooth^® Low Energy or Logi Bolt USB receiver.

Sustainable design considers environmental and social impacts from the moment raw materials are sourced right through to end-of-life. At Logitech, products are designed to deliver great user experiences and minimize environmental footprint, which is why a portion of the Signature M650’s plastic parts are made from post-consumer recycled (PCR) plastic – 64% for the graphite, 26% for off white and 26% for rose. Logitech’s PCR program illustrates the brand’s commitment to designing for sustainability and ensures that plastics in end-of-life consumer electronics are given a second life. Current initiatives for scaling this commitment mean that approximately half of the mice and keyboards in Logitech’s largest portfolio include some level of PCR plastic and that new product introductions will use PCR plastic, wherever possible. ​​

Pricing and Availability

The Signature M650 mice will be available in January 2022 on Logitech.com and at other global retailers. The suggested retail price for the Signature M650 and larger-sized Signature M650 L is $39.99. Signature M650 for Business will also be available for purchase globally. Please contact your local reseller or visit Logitech.com/workdesk.

About Logitech

Logitech helps all people pursue their passions by designing experiences so everyone can create, achieve, and enjoy more. Logitech designs and creates products that bring people together through computing, gaming, video, streaming and creating, and music. Brands of Logitech include Logitech, Logitech G, ASTRO Gaming, Streamlabs, Blue Microphones, Ultimate Ears and Jaybird. Founded in 1981, and headquartered in Lausanne, Switzerland, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech at www.logitech.com, the company blog or @Logitech.

Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company’s website at www.logitech.com.

(LOGIIR)

View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005225/en/

Wendy Spander

Logitech

1-510-713-5393

[email protected]

KEYWORDS: California Europe Switzerland United States North America

INDUSTRY KEYWORDS: Hardware Audio/Video Consumer Electronics Mobile/Wireless Technology

MEDIA:

Logo

Photo

Introducing the new Logitech Signature M650 Wireless Mouse, offering a more personalized experience with a choice of sizes including a left-handed option. (Photo: Business Wire)

European Commission Approves KAFTRIO^® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years

– More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic fibrosis for the first time –

LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label extension of KAFTRIO^® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

“We are delighted that KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor is now approved for these young patients in the European Union. It provides a new treatment option for physicians to help treat the underlying cause of this devastating disease early in life,” said Reshma Kewalramani, M.D., Chief Executive Officer and President at Vertex. “This important milestone brings us one step closer to our ultimate goal of developing treatments for all patients living with CF.”

“Ivacaftor/tezacaftor/elexacaftor plus ivacaftor has shown clinical benefit since its availability last year for people with CF ages 12 and above,” said Professor Marcus A. Mall, M.D., Head of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité University Medical Center Berlin. “CF is a progressive disease, in which symptoms and organ damage manifest very early in life. As a physician, I welcome the approval of this medicine for this younger age group, as it will help us treat eligible children with CF as early as 6 years old.”

As a result of long-term reimbursement agreements in Austria, Northern Ireland and Denmark, and provisions for access in health care systems such as Germany, eligible patients in these countries will have access to the expanded indication for KAFTRIO^® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor shortly following regulatory approval by the European Commission. Vertex will continue to work with reimbursement bodies across the European Union to ensure access for all eligible patients.

This medicine has also been approved by regulatory authorities in New Zealand and in Switzerland, where it is known as TRIKAFTA^® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), for people with CF ages 6 and above, and we continue to work closely with reimbursement bodies in these countries to ensure access for all eligible patients.

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 83,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing the CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the early 30s.

About KAFTRIO^® (ivacaftor/tezacaftor/elexacaftor) in A Combination Regimen With Ivacaftor

In people with certain types of mutations in the CFTR gene, the CFTR protein is not processed or folded normally within the cell, and this can prevent the CFTR protein from reaching the cell surface and functioning properly. KAFTRIO^® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is an oral medicine designed to increase the quantity and function of the CFTR protein at the cell surface. Elexacaftor and tezacaftor work together to increase the amount of mature protein at the cell surface by binding to different sites on the CFTR protein. Ivacaftor, which is known as a CFTR potentiator, is designed to facilitate the ability of CFTR proteins to transport salt and water across the cell membrane. The combined actions of ivacaftor, tezacaftor and elexacaftor help hydrate and clear mucus from the airways.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 12 consecutive years on Science magazine’s Top Employers list, one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies, and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex’s history of innovation, visit https://global.vrtx.com/ or follow us on Twitter and LinkedIn.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Reshma Kewalramani, M.D., Chief Executive Officer and President at Vertex, and Professor Marcus A. Mall, M.D., Head of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité University Medical Center Berlin, in this press release and statements regarding the estimated number of children eligible for a medicine that can treat the underlying cause of their disease for the first time, our beliefs regarding the benefits of our medicines, and the anticipated patient access to KAFTRIO^® in combination with ivacaftor. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include risks listed under the heading “Risk Factors” in Vertex’s annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company’s website at https://global.vrtx.com/ and www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005889/en/

Vertex Pharmaceuticals Incorporated

Investors:

Michael Partridge, +1 617-341-6108

or

Manisha Pai, +1 617-429-6891

Media:

[email protected]

or

International: +44 20 3204 5275

or

U.S.: +1 617-341-6992

KEYWORDS: Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Health Infectious Diseases Genetics Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo